The high rates of thrombotic complications observed in patients with severe COVID-19, combined with the current lack of an effective therapy for SARS-CoV-2, has led to significant interest regarding the use of antithrombotics for patients with COVID-19. In this regard, antithrombotic drugs which possess anti-inflammatory and/or antiviral properties have already entered clinical trials and will be discussed below (Figure 4).